Article
Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function.
Proceedings of the National Academy of Sciences of the United States of America - 19 Mar 2024
Silberstein John L, Du Jasper, Chan Kun-Wei, Frank Jessica A, Mathews Irimpan I, Kim Yong Bin, You Jia, Lu Qiao, Liu Jia, Philips Elliot A, Liu Phillip, Rao Eric, Fernandez Daniel, Rodriguez Grayson E, Kong Xiang-Peng, Wang Jun, Cochran Jennifer R
Abstract excerpt
Lymphocyte activation gene-3 (LAG-3) is an inhibitory receptor expressed on activated T cells and an emerging immunotherapy target. Domain 1 (D1) of LAG-3, which has been purported to directly interact with major histocompatibility complex class II (MHCII) and fibrinogen-like protein 1 (FGL1), has been the major focus for the development of therapeutic antibodies that inhibit LAG-3 receptor-ligand interactions...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.